In pharma R&D organizations and in hospital systems, any effort to glean novel insight from existing data represents a maddeningly difficult challenge.
So often, the experience of innovation at large pharmas can be disappointing and stifling, but occasionally, under the right circumstances, it is transformative and elating.
I see a new generation of researchers who grew up immersed in data+digital beginning to populate incumbent healthcare organizations+pharma companies, bringing with them a new set of expectations+capabilities. With time, effort, and a bit of luck, I sus…
This is a profoundly exciting and dynamic time in cancer research, as recent biological advances have revealed a range of therapeutic avenues and generated a palpable sense of hope and possibility. I am also encouraged by efforts utilizing data and tec…
Pharma desperately needs innovation; the question Safi Bahcall’s new book begs is whether senior pharma executives can structure their organizations in a fashion can liberate the creativity, and tolerate the uncertainty, innovation requires.
If appointed by President Trump to lead the FDA, Dr. Amy Abernethy would be a credit to the Administration, the Agency, and – mostly importantly – to the patients who would benefit from her vision, compassion, determination, and insight.
Data scientists are optimistic about the opportunity to improve how new medicines are discovered; most traditional medical scientists (including most pharma researchers) are skeptical these new approaches will deliver benefit to patients, but convincib…
Tech entrepreneurs should work closely with front-line innovators to ensure their company is focused on a relevant problem and developing an implementable solution; innovators must also recognize that robust evidence of impact (not just clicks) is esse…